Table 2.
Descriptive statistics for LVEF by treatmenta
| LL3 | Afatinib (40 mg/day) n = 229 | Chemotherapy n = 111 |
| Baseline LVEF, mean (SD) | 66.0 (6.90) | 66.60 (8.0) |
| Minimum LVEF during treatment, mean (SD) | 62.63 (6.33) | 68.87 (10.59) |
| % change from baseline to minimum, mean (SD) | −4.90 (9.95) | −1.06 (15.30) |
| Last LVEF during treatment, mean (SD) | 67.30 (7.10) | 68.90 (10.60) |
| % change from baseline to last, mean (SD) | 2.17 (11.41) | −1.06 (15.30) |
| LL1 | Afatinib (50 mg/day) n = 390 | Placebo n = 195 |
| Baseline LVEF, mean (SD) | 64.90 (6.60) | 63.90 (7.70) |
| Minimum LVEF during treatment, mean (SD) | 62.35 (6.57) | 63.73 (7.87) |
| % change from baseline to minimum, mean (SD) | −3.41 (9.14) | −0.88 (12.13) |
| Last LVEF during treatment, mean (SD) | 64.20 (7.0) | 64.40 (7.70) |
| % change from baseline to last, mean (SD) | −0.39 (10.40) | 0.27 (12.62) |
LVEF left ventricular ejection fraction, LL3 LUX-Lung 3, SD standard deviation, LL1 LUX-Lung 1, ECHO echocardiogram
aIn LL3, 208 patients in the afatinib arm and 15 patients in the chemotherapy arm had a follow-up ECHO; in LL1, 304 patients in the afatinib arm and 122 patients in the placebo arm had a follow-up ECHO